| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | AI841104, DEL22q13.3, KIAA1650, Proline rich synapse associated protein 2, Proline-rich synapse-associated protein 2, ProSAP2, PSAP2, SH3 and multiple ankyrin repeat domains 3, SH3 and multiple ankyrin repeat domains protein 3, SH3/ankyrin domain gene 3, SHAN3_HUMAN, Shank postsynaptic density protein, Shank3, Shank3b, SPANK 2, SPANK2 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Synthetic peptide amino acids 840-857 of rat Shank3 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
SHANK3 is a multidomain scaffolding protein located at the postsynaptic density of excitatory synapses. It anchors glutamate receptors, ion channels, and signaling proteins to the actin cytoskeleton, playing a vital role in synaptic structure and function.
SHANK3 is involved in receptor tyrosine kinase signaling, including the ERK-MAPK and PI3K pathways, which are essential for synaptic plasticity and neuronal survival. Mutations or deletions in SHANK3 are strongly associated with autism spectrum disorders and Phelan-McDermid syndrome, often resulting in impaired language and social communication.
In neurodegenerative disease, SHANK3 dysfunction contributes to synaptic disassembly and cognitive decline. Its role in maintaining synaptic integrity and regulating intracellular signaling makes SHANK3 a critical target for understanding and treating synaptic pathologies in both developmental and degenerative brain disorders.
1 µg/ml of SMC-336 was sufficient for detection of Shank3 in 10 µg COS cell lysate transiently transfected with Shank3 by colorimetric immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-336D — Size: 100 ug: SHANK3 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D, RRID: AB_2285907)
- SMC-336D-A390 — Size: 100 ug: SHANK3 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-A390, RRID: AB_2700584)
- SMC-336D-A488 — Size: 100 ug: SHANK3 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-A488, RRID: AB_2700585)
- SMC-336D-A594 — Size: 100 ug: SHANK3 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-A594, RRID: AB_2700587)
- SMC-336D-APC — Size: 100 ug: SHANK3 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-APC, RRID: AB_2700593)
- SMC-336D-BI — Size: 100 ug: SHANK3 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-BI, RRID: AB_2700594)
- SMC-336D-FITC — Size: 100 ug: SHANK3 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-FITC, RRID: AB_2700595)
- SMC-336D-HRP — Size: 100 ug: SHANK3 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-HRP, RRID: AB_2700596)
- SMC-336D-PCP — Size: 100 ug: SHANK3 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-PCP, RRID: AB_2700598)
- SMC-336D-RPE — Size: 100 ug: SHANK3 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336D-RPE, RRID: AB_2700599)
- SMC-336S — Size: 12 ug: SHANK3 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-336S, RRID: AB_2285907)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Schuetz G., et al. (2004) JCB. 167(5): 645-952.
3. Durand C.M., et al. (2007) Nature Genetics. 39: 25-27.